29th - 30th October, 2020

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress (Time Zone - GREENWHICH MEAN TIME(GMT))

40+
Speakers
10+
Networking Hours
12
Sessions
200+
Attendees

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

users

30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy

users

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

users

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 29th - 30th October 2020 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT
Why Attend?
  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Sessions 
Key Highlights
  • Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Biomarkers and Cancer Vaccines
  • CAR-T cell therapy, T Cell Therapy
  • Tumor microenvironment
  • Oncolytic Viruses
  • Microbiome in Cancer Immunotherapy
CONFERENCE AGENDA
Advances in IO
Personalized Immunotherapy, Vaccines and Oncolytic Viral Therapy
CONFERENCE SPEAKERS
Advisors
Stefan Gluck

Stefan Gluck

Vice President, Global Head Franchise Oncology
Regeneron

Stefan Gluck

Vice President, Global Head Franchise Oncology
Regeneron
Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy
Kings College London, UK

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy
Kings College London, UK
Speakers
Roy Baynes

Roy Baynes

Senior Vice President and Head, Global Clinical Development, Chief Medical Officer
Merck Sharp & Dohme

Roy Baynes

Senior Vice President and Head, Global Clinical Development, Chief Medical Officer
Merck Sharp & Dohme
Bruno Tullia

Bruno Tullia

Assistant Professor, Immunology
University of Pittsburgh

Bruno Tullia

Assistant Professor, Immunology
University of Pittsburgh
Illip Burmester, Ph.D.

Illip Burmester, Ph.D.

Scientific Sales Support Europe
Proteome Sciences

Illip Burmester, Ph.D.

Scientific Sales Support Europe
Proteome Sciences
David Gilham

David Gilham

Vice President, R&D
Celyad, UK

David Gilham

Vice President, R&D
Celyad, UK
John Maher

John Maher

Consultant & Senior Lecturer
King’s College London

John Maher

Consultant & Senior Lecturer
King’s College London
Sheeba Irshad

Sheeba Irshad

CRUK Clinician Scientist & Honorary Medical Oncologist
Guys Hospital, UK

Sheeba Irshad

CRUK Clinician Scientist & Honorary Medical Oncologist
Guys Hospital, UK
Will Arends

Will Arends

Chartered (UK) and European Patent Attorney
Marks & Clerk, UK

Will Arends

Chartered (UK) and European Patent Attorney
Marks & Clerk, UK
Markus Zettl

Markus Zettl

Director, Immuno-Oncology
Pieris Pharmaceuticals, Germany

Markus Zettl

Director, Immuno-Oncology
Pieris Pharmaceuticals, Germany
SPONSORS
Leading Partner
example-image

GenScript

example-image

Personalis

Gold
example-image

Proteome Sciences

Silver
example-image

Miltenyi Biotec

example-image

Ultivue

Speaking Partner
example-image

PromoCell

example-image

TransCure bioServices

example-image

MBL International

example-image

HalioDx

example-image

Marks & Clerk

example-image

PHC Group

example-image

Crown Bioscience

Primary Partner
example-image

Imaging Endpoints

example-image

Thermo Fisher Scientific

example-image

Aquila BioMedical

example-image

Horizon Discovery

Exhibition Partner
example-image

Mi-mAbs

example-image

KDBIO

example-image

Synthace

PARTNERS
Supporting Association
MabDesign

MabDesign

One Nucleus

One Nucleus

Media Partners
example-image

Technology Networks

example-image

Pharma Journalist

example-image

PharmaTutor

example-image

GEN

example-image

MedNous

example-image

Medical events guide

NEWS
PAST EVENT GALLERY